How Investors May Respond To InnoCare Pharma (SEHK:9969) Advancing Novel B7-H3 ADC and Next-Gen TRK Inhibitor

Simply Wall St.
Nov 02

InnoCare Pharma recently announced two key milestones: the first patient was dosed in the clinical trial of their novel B7-H3 targeted antibody-drug conjugate (ADC) ICP-B794 in China, and positive ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10